Financhill
Sell
34

BCDA Quote, Financials, Valuation and Earnings

Last price:
$2.06
Seasonality move :
9.64%
Day range:
$2.00 - $2.08
52-week range:
$1.63 - $4.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.78x
P/B ratio:
13.64x
Volume:
33.4K
Avg. volume:
56.7K
1-year change:
-29.12%
Market cap:
$10.7M
Revenue:
$58K
EPS (TTM):
-$2.58

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BCDA
BioCardia
-- -$0.87 -100% -36.96% $6.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
SNTI
Senti Biosciences
$250K -$0.90 -- -63.27% $13.50
SWTX
SpringWorks Therapeutics
$74.9M -$0.97 22.87% -79.63% $47.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BCDA
BioCardia
$2.06 $6.00 $10.7M -- $0.00 0% 16.78x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.44 $1.00 $1M -- $0.00 0% 0.46x
SNTI
Senti Biosciences
$2.25 $13.50 $58.7M -- $0.00 0% 4.66x
SWTX
SpringWorks Therapeutics
$46.99 $47.00 $3.5B -- $0.00 0% 15.92x
TOVX
Theriva Biologics
$0.44 $7.00 $3.6M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BCDA
BioCardia
-- -2.048 -- 0.35x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
SNTI
Senti Biosciences
-- -2.335 -- --
SWTX
SpringWorks Therapeutics
-- 1.839 -- 3.99x
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BCDA
BioCardia
-- -$2.7M -938.6% -938.6% -54966.67% -$1.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
SNTI
Senti Biosciences
-- -$16.4M -- -- -- -$14.1M
SWTX
SpringWorks Therapeutics
$45.6M -$80.5M -49.69% -49.69% -167.44% -$68.8M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

BioCardia vs. Competitors

  • Which has Higher Returns BCDA or NBY?

    NovaBay Pharmaceuticals has a net margin of -54866.67% compared to BioCardia's net margin of -49.65%. BioCardia's return on equity of -938.6% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    BCDA
    BioCardia
    -- -$0.59 -$2M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About BCDA or NBY?

    BioCardia has a consensus price target of $6.00, signalling upside risk potential of 194.12%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that BioCardia has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioCardia is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BCDA
    BioCardia
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is BCDA or NBY More Risky?

    BioCardia has a beta of 0.814, which suggesting that the stock is 18.633% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock BCDA or NBY?

    BioCardia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCardia pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BCDA or NBY?

    BioCardia quarterly revenues are $3K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioCardia's net income of -$2.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, BioCardia's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCardia is 16.78x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BCDA
    BioCardia
    16.78x -- $3K -$2.7M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns BCDA or OGEN?

    Oragenics has a net margin of -54866.67% compared to BioCardia's net margin of --. BioCardia's return on equity of -938.6% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BCDA
    BioCardia
    -- -$0.59 -$2M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About BCDA or OGEN?

    BioCardia has a consensus price target of $6.00, signalling upside risk potential of 194.12%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than BioCardia, analysts believe Oragenics is more attractive than BioCardia.

    Company Buy Ratings Hold Ratings Sell Ratings
    BCDA
    BioCardia
    1 0 0
    OGEN
    Oragenics
    0 1 0
  • Is BCDA or OGEN More Risky?

    BioCardia has a beta of 0.814, which suggesting that the stock is 18.633% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock BCDA or OGEN?

    BioCardia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCardia pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BCDA or OGEN?

    BioCardia quarterly revenues are $3K, which are larger than Oragenics quarterly revenues of --. BioCardia's net income of -$2.7M is lower than Oragenics's net income of -$2.2M. Notably, BioCardia's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCardia is 16.78x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BCDA
    BioCardia
    16.78x -- $3K -$2.7M
    OGEN
    Oragenics
    0.46x -- -- -$2.2M
  • Which has Higher Returns BCDA or SNTI?

    Senti Biosciences has a net margin of -54866.67% compared to BioCardia's net margin of --. BioCardia's return on equity of -938.6% beat Senti Biosciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BCDA
    BioCardia
    -- -$0.59 -$2M
    SNTI
    Senti Biosciences
    -- -$14.10 --
  • What do Analysts Say About BCDA or SNTI?

    BioCardia has a consensus price target of $6.00, signalling upside risk potential of 194.12%. On the other hand Senti Biosciences has an analysts' consensus of $13.50 which suggests that it could grow by 500%. Given that Senti Biosciences has higher upside potential than BioCardia, analysts believe Senti Biosciences is more attractive than BioCardia.

    Company Buy Ratings Hold Ratings Sell Ratings
    BCDA
    BioCardia
    1 0 0
    SNTI
    Senti Biosciences
    1 0 0
  • Is BCDA or SNTI More Risky?

    BioCardia has a beta of 0.814, which suggesting that the stock is 18.633% less volatile than S&P 500. In comparison Senti Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BCDA or SNTI?

    BioCardia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCardia pays -- of its earnings as a dividend. Senti Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BCDA or SNTI?

    BioCardia quarterly revenues are $3K, which are larger than Senti Biosciences quarterly revenues of --. BioCardia's net income of -$2.7M is higher than Senti Biosciences's net income of -$14.1M. Notably, BioCardia's price-to-earnings ratio is -- while Senti Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCardia is 16.78x versus 4.66x for Senti Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BCDA
    BioCardia
    16.78x -- $3K -$2.7M
    SNTI
    Senti Biosciences
    4.66x -- -- -$14.1M
  • Which has Higher Returns BCDA or SWTX?

    SpringWorks Therapeutics has a net margin of -54866.67% compared to BioCardia's net margin of -169.47%. BioCardia's return on equity of -938.6% beat SpringWorks Therapeutics's return on equity of -49.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    BCDA
    BioCardia
    -- -$0.59 -$2M
    SWTX
    SpringWorks Therapeutics
    92.82% -$1.11 $417.4M
  • What do Analysts Say About BCDA or SWTX?

    BioCardia has a consensus price target of $6.00, signalling upside risk potential of 194.12%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $47.00 which suggests that it could grow by 0.02%. Given that BioCardia has higher upside potential than SpringWorks Therapeutics, analysts believe BioCardia is more attractive than SpringWorks Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BCDA
    BioCardia
    1 0 0
    SWTX
    SpringWorks Therapeutics
    0 3 0
  • Is BCDA or SWTX More Risky?

    BioCardia has a beta of 0.814, which suggesting that the stock is 18.633% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.589%.

  • Which is a Better Dividend Stock BCDA or SWTX?

    BioCardia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCardia pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BCDA or SWTX?

    BioCardia quarterly revenues are $3K, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.1M. BioCardia's net income of -$2.7M is higher than SpringWorks Therapeutics's net income of -$83.2M. Notably, BioCardia's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCardia is 16.78x versus 15.92x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BCDA
    BioCardia
    16.78x -- $3K -$2.7M
    SWTX
    SpringWorks Therapeutics
    15.92x -- $49.1M -$83.2M
  • Which has Higher Returns BCDA or TOVX?

    Theriva Biologics has a net margin of -54866.67% compared to BioCardia's net margin of --. BioCardia's return on equity of -938.6% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BCDA
    BioCardia
    -- -$0.59 -$2M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About BCDA or TOVX?

    BioCardia has a consensus price target of $6.00, signalling upside risk potential of 194.12%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1498.17%. Given that Theriva Biologics has higher upside potential than BioCardia, analysts believe Theriva Biologics is more attractive than BioCardia.

    Company Buy Ratings Hold Ratings Sell Ratings
    BCDA
    BioCardia
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is BCDA or TOVX More Risky?

    BioCardia has a beta of 0.814, which suggesting that the stock is 18.633% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock BCDA or TOVX?

    BioCardia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCardia pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BCDA or TOVX?

    BioCardia quarterly revenues are $3K, which are larger than Theriva Biologics quarterly revenues of --. BioCardia's net income of -$2.7M is higher than Theriva Biologics's net income of -$4.3M. Notably, BioCardia's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCardia is 16.78x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BCDA
    BioCardia
    16.78x -- $3K -$2.7M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 40.18% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is down 22.06% over the past day.

Buy
67
GBX alert for Jul 3

Greenbrier Companies [GBX] is up 21.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock